DO NOT USE-Draft dp
Primary care is the initial access point for the diagnosis and treatment of depression. However, the recognition of major depressive episodes in patients seen in primary care is low. By providing awareness of the incidence, predisposing risk factors of depression and its impact on patient outcomes, primary care providers will attain the foundational competence to identify patients presenting with depression in their settings. By using a screening process that is incorporated into the vital assessment process, screening for depression can easily be adapted into the workflow. Screening for depression has a CPT code that is reimbursable by CMS and commercial insurance.
This training will provide the content and competence for primary care providers to gain confidence in the necessity for incorporating standard measures of screening and identifying patients with depression. Additionally, this program will provide an introduction to the measurement based care approach and describe how it can be integrated into current practices.
This CME activity is designed to meet the educational needs of primary care physicians, nurse practitioners, and physician assistants, particularly those serving underserved and vulnerable populations.
At the conclusion of this activity, the participant should be able to:
- State three symptoms of major depressive disorder.
- Describe how depression contributes to the overall disease process.
- Identify one tool used to screen patients for depression.
- Describe the prevalence of depression in underserved populations.
Madhukar H. Trivedi, MD, Presenter
Betty Jo Hay Distinguished Chair in Mental Health
Professor of Psychiatry
Director Comprehensive Center for Depression
Department of Psychiatry
University of Texas Southwestern Medical Center
Consulting: Madhukar H. Trivedi is or has been an advisor/consultant to, Alkermes, AstraZeneca, Bristol-Myers Squibb Company, Cephalon, Inc., Cerecor, Concert Pharmaceuticals, Inc., Eli Lilly & Company, Evotec, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Global Services, LLC/Janssen Pharmaceutica Products, LP/Johnson & Johnson PRD, Lundbeck, MedAvante, Medtronic, Merck, Mitsubishi Tanabe Pharma Development America, Inc., Naurex, Neuronetics, Otsuka Pharmaceuticals, Pamlab, Pfizer Inc., Phoenix Marketing Solutions, Rexahn Pharmaceuticals, Ridge Diagnostics, Roche Products Ltd ., Sepracor, SHIRE Development, Sunovion, Takeda, Vivus, and Wyeth-Ayerst Laboratories.
Research Activities: In addition, he has received research support from: Agency for Healthcare Research and Quality (AHRQ), National Alliance for Research in Schizophrenia and Depression, National Institute of Mental Health, National Institute on Drug Abuse, National Institute of Diabetes and Digestive Disorders.
Formal Advisory: Member, Scientific Advisory Board for the Canadian Biomarker Integration Network for Depression (CAN BIND) project (2014). Special Emphasis Panel, ZMH1 ERB – I (04), National Institute of Mental Health (NIMH), Mentored Career Development Award to Build Research Capacity in Global Mental Health, April 9, 2014.
- 0.75 AMA
- 0.75 Attendance
- 0.75 Ethics
Hardware/software requirements: Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox, and Google Chrome.